Dongkoo Bio&Pharma
VC Fund
Dongkoo Bio&Pharma is an bio&Pharma Company.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries Dongkoo Bio&Pharma invests in
Stages Dongkoo Bio&Pharma invests in
Countries Dongkoo Bio&Pharma invests in
Investment Focus
Industry
- Biotechnology 2 (67%)
- Pharmaceutical 2 (67%)
- Biopharma 1 (33%)
- Health Care 1 (33%)
- Therapeutics 1 (33%)
Stage
- Series A 2 (67%)
- Seed 1 (33%)
Country
- United States 2 (67%)
- South Korea 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Valted Seq is a discovery stage biopharmaceutical company that utilizes big data to develop lifesaving therapeutics.focused on the discovery of neurodegenerative pathways and biomarkers to inform and accelerate the development of new therapeutics and diagnostics, including companion diagnostics which play a critical role in enabling advancedtherapeutics. To achieve this, the company has created the world’s largest repository of single-cell sequencing data from high-quality, clinically characterized brain tissues of patients with neurodegenerative diseases including Alzheimer’s and Parkinson’s.It was established in Gaithersburg, Maryland by | $10M / Seed / Nov 02, 2021 | ||
| Neuraly, a startup biotech company, was formed in 2016 following foundational research by world class neuroscientists led by Ted Dawson, M.D., Ph.D., Leonard and Madlyn Abramson Professor in Neurodegenerative Diseases and Director of the Institute for Cell Engineering at the Johns Hopkins School of Medicine. Following the acquisition of exclusivelicenses to patents covering the composition of matter and methods of use, research supporting the development of NLY01 was recently published in Nature Medicine1. These data demonstrated the critical role of the glial compartment of the neural tissue in the pathogenesis of neurodegenerative diseases such as Parkinson's and Alzheimer's diseases. | $36M / Series A / Jul 18, 2018 | ||
| D&D Pharmatech is a operator of a holding company created to fund the development of therapeutic medicines through disease-specific subsidiary companies founded and guided by top-tier medical research faculty. The company's product pipeline focuses on a range of indications including neurodegenerative, metabolic and fibrotic diseases,providing the opportunity to accelerate the translation of cutting-edge research into lifesaving therapeutic products for patients. | $36M / Series A / Jan 01, 2018 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Dongkoo Bio&Pharma invest in?
Dongkoo Bio&Pharma invests primarily in Biotechnology, Pharmaceutical and Biopharma startups, most often at Series A and Seed stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Dongkoo Bio&Pharma last invest?
The most recent investment recorded for Dongkoo Bio&Pharma closed in Nov 2021. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
